

PA-124. Evaluating the Most Influential Factors in Decision-Making in Women and Men with Relapsed Multiple Myeloma

BACKGROUND

Gender's influence on treatment decision-making in Refractory/Relapsed Multiple Myeloma (RRMM) presents complex healthcare challenges. This study analyzes gender-based factors affecting RRMM treatment choices.

METHODOLOGY

This online survey was administered via **HealthTree Cure Hub® (PMID: 35271305)** from **February 14 to November 8, 2023.**

The 30-question survey covered 11 decision-making domains at treatment changes, categorizing influential factors as treatment, patient, or myeloma related.

Patients rated using a 5-point scale (1=not influential, 5=extremely influential). Patients with ≥1 relapse were stratified by gender.

Results were reported as numbers and percentages.

CONCLUSION

The survey results indicate that **men and women consider a similar set of factors to be most influential in their treatment decision-making process following a multiple myeloma relapse.**

Treatment-related factors include efficacy, meeting criteria, availability, and potential side effects severity. Both genders also emphasized patient-related factors such as quality of life and the ability to self-care as crucial, as well as disease-related factors like the aggressiveness of the relapsing myeloma, duration of previous response, and organ involvement as critical. While both genders agree on the importance of these factors, statistically **significant differences were observed in their ratings, with women consistently scoring them higher.** This suggests subtle but significant gender differences in treatment decision-making after a multiple myeloma relapse.

ACKNOWLEDGEMENT


Our deepest gratitude to the patients and caregivers who share their data and experiences through the HealthTree Cure Hub®. Your contributions make this research possible.

Authors: Martha Paola Anchondo Commesse, MD^{1*}, Felipe Flores Quiroz, MD¹, Patricia Alejandra Flores Pérez, MD¹, Jorge Arturo Hurtado Martinez, MD, MHSc¹, Andrea Isabel Robles Espinoza, MD, MBA¹, Jennifer M. Ahlstrom, BS¹, Laura Ladeluca, PhD², Julie Strain, MMH², Rachel M. Jensen, BS^{3*}, Cynthia Chmielewski¹, Robert Z. Orłowski, MD, PhD³, Sagar Lonial, MD, FACP⁴, Rafael Fonseca, MD⁵, Ola Landgren, MD, PhD⁶, Saad Z. Usmani, MD, MBA, FACP, FASCO⁷, Jay Hydren, PhD^{1*}.

Organizations: ¹HealthTree Foundation, Lehi, UT; ²GlaxoSmithKline plc, Durham, NC; ³The University of Texas MD Anderson Cancer Center, Houston, TX; ⁴Winship Cancer Institute Of Emory University, Atlanta,GA; ⁵Mayo Clinic, Scottsdale, AZ; ⁶University of Miami Sylvester Comprehensive Cancer Center, Miami, FL; ⁷Memorial Sloan Kettering Cancer Center, New York, NY.


RESULTS

GENDER DISEASE-RELATED FACTORS




For your first change in therapy (relapse), please indicate to what degree each of your myeloma disease-related factors went into your decision. (Does not include dosage changes)

GENDER TREATMENT-RELATED FACTORS



For your first change in therapy (relapse), please indicate to what degree each treatment-related factor went into your treatment decision, not including dosage change. Male v Female

GENDER PATIENT FACTORS



For your first change in therapy (relapse), please indicate to what degree each patient factor (functional/quality of life) went into your decision. Male v Female

DEMOGRAPHICS

Total Participants: 688 Respondents, 289 were Refractory/Relapsed Multiple Myeloma patients

Age: 66±9 years

Gender Distribution: 289 total participants. 152 (53%) were female, 137 (47%) were male

Ethnicity Distribution: 91% were white

Education: 48% had professional school education

